



: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:31AM

Received

: 09/Nov/2024 10:05AM : 09/Nov/2024 01:45PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF HAEMATOLOGY**

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

----

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology

SIN No:BED240245657

1 of 15

Page 1 of 15





: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:31AM

Received

: 09/Nov/2024 10:05AM

: Final Report

Reported

Status

: 09/Nov/2024 01:45PM

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF HAEMATOLOGY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	10.3	g/dL	12-15	CYANIDE FREE COLOUROMETER
PCV	33.60	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	4.29	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	78.4	fL	83-101	Calculated
MCH	24	pg	27-32	Calculated
MCHC	30.6	g/dL	31.5-34.5	Calculated
R.D.W	18.2	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	9,550	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT	(DLC)			
NEUTROPHILS	63.1	%	40-80	Electrical Impedance
LYMPHOCYTES	25.9	%	20-40	Electrical Impedance
EOSINOPHILS	3.5	%	1-6	Electrical Impedance
MONOCYTES	6.9	%	2-10	Electrical Impedance
BASOPHILS	0.6	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	6026.05	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2473.45	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	334.25	Cells/cu.mm	20-500	Calculated
MONOCYTES	658.95	Cells/cu.mm	200-1000	Calculated
BASOPHILS	57.3	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	2.44		0.78- 3.53	Calculated
PLATELET COUNT	334000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	25	mm at the end of 1 hour	0-20	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC WITH FEW MICROCYTIC HYPOCHROMIC CELLS.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

Page 2 of 15



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:BED240245657





: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No Visit ID

: SCHI.0000025214 : SCHIOPV38929

Ref Doctor Emp/Auth/TPA ID : SFSDFGS

: Dr.SELF

Collected

: 09/Nov/2024 09:31AM

Received Reported : 09/Nov/2024 10:05AM : 09/Nov/2024 01:45PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF HAEMATOLOGY**

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:BED240245657

Page 3 of 15





 Patient Name
 : Mrs.SAVITA .

 Age/Gender
 : 36 Y 7 M 25 D/F

 UHID/MR No
 : SCHI.0000025214

Visit ID : SCHIOPV38929

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SFSDFGS Collected : 09/Nov/2024 09:31AM
Received : 09/Nov/2024 10:05AM
Reported : 09/Nov/2024 01:51PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF HAEMATOLOGY**

## ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
<b>BLOOD GROUP ABO AND RH FACTOR</b>	, WHOLE BLOOD EDTA			
BLOOD GROUP TYPE	В			Forward & Reverse Grouping with Slide/Tube Aggluti
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination

Page 4 of 15









: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No Visit ID : SCHI.0000025214

Ref Doctor

: SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 01:51PM

Received

: 09/Nov/2024 02:55PM : 09/Nov/2024 04:41PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF BIOCHEMISTRY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GLUCOSE, FASTING, NAF PLASMA	106	mg/dL	70-100	GOD - POD

#### **Comment:**

## As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

#### Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Test Name	Result	Unit	Bio. Ref. Interval	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	133	mg/dL	70-140	GOD - POD

#### **Comment:**

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 5 of 15



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:PLP1488010







: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:32AM

Received

: 09/Nov/2024 12:57PM

Reported Status

: 09/Nov/2024 03:22PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF BIOCHEMISTRY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
HBA1C (GLYCATED HEMOGLOBIN),	WHOLE BLOOD EDTA			
HBA1C, GLYCATED HEMOGLOBIN	5.6	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	114	mg/dL		Calculated

#### **Comment:**

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 – 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic


Control by American Diabetes Association guidelines 2023.

- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control A: HbF >25%
  - B: Homozygous Hemoglobinopathy.

(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 6 of 15





SIN No:EDT240094067





: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID

: SCHIOPV38929

Ref Doctor Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:32AM

Received

: 09/Nov/2024 10:02AM

Reported

Status

: 09/Nov/2024 01:23PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF BIOCHEMISTRY**

## ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
LIPID PROFILE, SERUM				<u>'</u>
TOTAL CHOLESTEROL	184	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	140	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	41	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	143	mg/dL	<130	Calculated
LDL CHOLESTEROL	115	mg/dL	<100	Calculated
VLDL CHOLESTEROL	28	mg/dL	<30	Calculated
CHOL / HDL RATIO	4.49		0-4.97	Calculated
ATHEROGENIC INDEX (AIP)	0.17		<0.11	Calculated


#### **Comment:**

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

Page 7 of 15









: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:32AM

Received

: 09/Nov/2024 10:02AM

Reported

Status

: 09/Nov/2024 01:23PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF BIOCHEMISTRY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
LIVER FUNCTION TEST (LFT), SERUM		'		
BILIRUBIN, TOTAL	0.70	mg/dL	0.20-1.30	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.30	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	0.40	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	24	U/L	<35	Visible with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	32.0	U/L	14-36	UV with P-5-P
AST (SGOT) / ALT (SGPT) RATIO (DE RITIS)	1.3		<1.15	Calculated
ALKALINE PHOSPHATASE	78.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	8.30	g/dL	6.3-8.2	Biuret
ALBUMIN	4.70	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.60	g/dL	2.0-3.5	Calculated
A/G RATIO	1.31		0.9-2.0	Calculated

## **Comment:**

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin) Common patterns seen:

- 1. Hepatocellular Injury:
- \*AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.\*ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with ALP. AST: ALT (ratio) – In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.
- 2. Cholestatic Pattern:\*ALP Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in pregnancy, impacted by age and sex.\*Bilirubin elevated- predominantly direct, To establish the hepatic origin correlation with elevated GGT helps.
- 3. Synthetic function impairment:\*Albumin-Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
- 4. Associated tests for assessment of liver fibrosis Fibrosis-4 and APRI Index.

Page 8 of 15









: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:32AM

Received

: 09/Nov/2024 10:02AM

Reported

Status

: 09/Nov/2024 01:23PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF BIOCHEMISTRY**

## ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
RENAL PROFILE/KIDNEY FUNCTION	TEST (RFT/KFT), SEF	RUM	1	
CREATININE	0.60	mg/dL	0.5-1.04	Creatinine amidohydrolase
UREA	19.60	mg/dL	15-36	Urease
BLOOD UREA NITROGEN	9.2	mg/dL	8.0 - 23.0	Calculated
URIC ACID	5.30	mg/dL	2.5-6.2	Uricase
CALCIUM	10.90	mg/dL	8.4 - 10.2	Arsenazo-III
PHOSPHORUS, INORGANIC	3.20	mg/dL	2.5-4.5	PMA Phenol
SODIUM	143	mmol/L	135-145	Direct ISE
POTASSIUM	5.2	mmol/L	3.5-5.1	Direct ISE
CHLORIDE	112	mmol/L	98 - 107	Direct ISE
PROTEIN, TOTAL	8.30	g/dL	6.3-8.2	Biuret
ALBUMIN	4.70	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.60	g/dL	2.0-3.5	Calculated
A/G RATIO	1.31		0.9-2.0	Calculated

Page 9 of 15









: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No Visit ID : SCHI.0000025214

Ref Doctor

: SCHIOPV38929 : Dr.SELF

Emp/Auth/TPA ID : SFSDFGS

Collected

: 09/Nov/2024 09:32AM

Received Reported : 09/Nov/2024 10:02AM : 09/Nov/2024 10:51AM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF BIOCHEMISTRY**

## ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	32.00	U/L	12-43	Glyclyclycine Nitoranalide

Page 10 of 15











: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:32AM

Received

: 09/Nov/2024 12:58PM : 09/Nov/2024 02:40PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF IMMUNOLOGY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
THYROID PROFILE TOTAL (T3, T4, TSF	l), SERUM			
TRI-IODOTHYRONINE (T3, TOTAL)	1.1	ng/mL	0.87-1.78	CLIA
THYROXINE (T4, TOTAL)	10.49	μg/dL	5.48-14.28	CLIA
THYROID STIMULATING HORMONE (TSH)	5.512	μIU/mL	0.38-5.33	CLIA

#### **Comment:**


For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)
First trimester	0.1 - 2.5
Second trimester	0.2 - 3.0
Third trimester	0.3 - 3.0

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- **4.** Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	T3	<b>T4</b>	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Treatment.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes

Page 11 of 15





SIN No:SPL24146223







: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:32AM

Received

: 09/Nov/2024 12:58PM

Reported

Status

: 09/Nov/2024 02:40PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF IMMUNOLOGY**

## ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

	High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma
--	------	------	------	------	--

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

SIN No:SPL24146223



Page 12 of 15





: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:32AM

Received

: 09/Nov/2024 01:44PM

Reported Status

: 09/Nov/2024 01:53PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF CLINICAL PATHOLOGY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
COMPLETE URINE EXAMINATION (	CUE) , URINE			
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Physical Measuremen
рН	6.0		5-7.5	Double Indicator
SP. GRAVITY	1.030		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	Protein Error Of Indicator
GLUCOSE	NEGATIVE		NEGATIVE	Glucose Oxidase
URINE BILIRUBIN	NEGATIVE		NEGATIVE	Azo Coupling Reaction
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	Sodium Nitro Prusside
UROBILINOGEN	NORMAL		NORMAL	Modifed Ehrlich Reaction
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	Leucocyte Esterase
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOPY	1		
PUS CELLS	2-4	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1-2	/hpf	<10	Microscopy
RBC	ABSENT	/hpf	0-2	Microscopy
CASTS	ABSENT		0-2 Hyaline Cast	Microscopy
CRYSTALS	ABSENT		ABSENT	Microscopy

#### **Comment:**

All urine samples are checked for adequacy and suitability before examination. All abnormal chemical examination are rechecked and verified by manual methods. Microscopy findings are reported as an average of 10 high power fields.

Page 13 of 15



Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:UR2419305





: Mrs.SAVITA .

Age/Gender : 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID

: SCHIOPV38929

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:32AM

Received

: 09/Nov/2024 01:44PM : 09/Nov/2024 01:53PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF CLINICAL PATHOLOGY**

## ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	GOD-POD
Test Name	Result	Unit	Bio. Ref. Interval	Method
URINE GLUCOSE(FASTING)	NEGATIVE		NEGATIVE	GOD-POD

Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:UF012152

Page 14 of 15









: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929 : Dr.SELF

Emp/Auth/TPA ID : SFSDFGS

Collected

: 09/Nov/2024 03:23PM

Received

: 09/Nov/2024 07:49PM

Reported

: 11/Nov/2024 10:05AM

Status Sponsor Name : Final Report


: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF CYTOLOGY**

LBC PAP SMEAR, CERVICAL BRUSH SAMPLE							
	CYTOLOGY NO.	L/1769/24					
I	SPECIMEN						
a	SPECIMEN ADEQUACY	NOT ADEQUATE					
b	SPECIMEN TYPE	LIQUID-BASED PREPARATION (LBC)					
	SPECIMEN NATURE/SOURCE	CERVICAL SMEAR					
С	COMMENTS	UNSATISFACTORY FOR EVALUATION					
d	REASON FOR UNSATISFACTORY SMEAR	SQUAMOUS CELLS ARE OBSCURED BY INFLAMMATION.					
II	MICROSCOPY	Smears are unsatisfactory for evaluation, >75% squamous cells are obscured by inflammation.					
III	RESULT						
a	EPITHEIAL CELL						
IV	RECOMMENDATIONS CONSIDER CERVICAL CYTOLOGY RE-EVALUATION AFTER TREATMENT OF INFECTION						
Pap Test	t is a screening test for cervical cancer with inher	rent false negative results. Regular screening and follow-up is recommended					

(Bethesda-TBS-2014) revised

\*\*\* End Of Report \*\*\*



SIN No:CS085763



Page 15 of 15





Patient Name : Mrs.SAVITA . Age/Gender : 36 Y 7 M 25 D/F UHID/MR No : SCHI.0000025214

Visit ID : SCHIOPV38929

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SESDEGS Collected : 09/Nov/2024 03:23PM Received : 09/Nov/2024 07:49PM Reported


Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

: 11/Nov/2024 10:05AM

#### TERMS AND CONDITIONS GOVERNING THIS REPORT

- 1. Reported results are for information and interpretation of the referring doctor or such other medical professionals, who understandreporting units, reference ranges and limitation of technologies. Laboratories not be responsible for any interpretation whatsoever.
- 2. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the verifications of parrticulars have been confirmed by the patient or his / her representative at the point of generation of said specimen.
- 3. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same parameter for the same patient (within subject biological variation).
- 4. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be communicated to the assigned regulatory bodies.
- 5. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of the laboratory.
- 6. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only.



SIN No:CS085763





Congulleties

Name : Mrs. SAVITA . Age: 36 Y UHID:SCHI.0000025214 Sex: F \*SCHI.0000025214\* Address: DAKSHINPURI OP Number: SCHIOPV38929 : ARCOFEMI MEDIWHEEL FEMALE AHC CREDIT PAN Bill No: SCHI-OCR-12903 Plan INDIA OP AGREEMENT Date : 09.11.2024 09:25 Sno Serive Type/ServiceName Department ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324 I GAMMA GLUTAMYL TRANFERASE (GGT) 22 D ECHO 3 LIVER FUNCTION TEST (LFT) 4 GLUCOSE, FASTING 5 HEMOGRAM + PERIPHERAL SMEAR -6 GYNAECOLOGY CONSULTATION Dr Juvalor 7 DIET CONSULTATION 8 COMPLETE URINE EXAMINATION 9 URINE GLUCOSE(POST PRANDIAL) 10 PERIPHERAL SMEAR HECG 12 LBC PAP TEST- PAPSURE 13 RENAL PROFILE/RENAL FUNCTION TEST (RFT/KFT) 14 DENTAL CONSULTATION 15 GLUCOSE, POST PRANDIAL (PP), 2 HOURS (POST MEAL) 16 URINE GLUCOSE(FASTING) 17 HbA1c, GLYCATED HEMOGLOBING 18 X-RAY CHEST PA 19 ENT CONSULTATION 20 FITNESS BY GENERAL PHYSICIAN 21 BLOOD GROUP ABO AND RH FACTOR L 22 LIPID PROFILE 23 BODY MASS INDEX (BMI) 24 OPTHAL BY GENERAL PHYSICIAN 2. ULTRASOUND - WHOLE ABDOMEN 26 THYROID PROFILE (TOTAL T3, TOTAL T4, TSH)

> Height: (U) C Weight: (2 - 6 B.P: (02 M) Pulse: (99

## PHC Desk

From:

noreply@apolloclinics.info

Sent:

08 November 2024 15:03

To:

manojmahamna 105@gmail.com

Cc:

phc.klc@apollospectra.com; syamsunder.m@apollohl.com;

cc.klc@apollospectra.com

Subject:

Your appointment is confirmed



## Dear Savita K.

Greetings from Apollo Clinics,

Your corporate health check appointment is confirmed at SPECTRA NEHRU ENCLAVE clinic on 2024-

Payment Mode	
Corporate Name	ARCOFEMI HEALTHCARE LIMITED
Agreement Name	[ARCOFEMI MEDIWHEEL FEMALE AHC CREDIT PAN INDIA OP AGREEMENT]
Package Name <sup>c</sup>	[ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324]

"Kindly carry with you relevant documents such as HR issued authorization letter and or appointment confirmation mail and or valid government ID proof and or company ID card and or voucher as per our agreement with your company or sponsor."

Note: Video recording or taking photos inside the clinic premises or during camps is not allowed and would attract legal consequences.

Note: Also once appointment is booked, based on availability of doctors at clinics tests will happen, any pending test will happen based on doctor availability and clinics will be updating the same to customers.

Instructions to be followed for a health check:

NUAL PLUS



(2) WhatsApp



3 of 4

			Anollo Choctro
Name:	SAVITA	Age/Sex:	Apollo Spectra
UHID:	25211		HOSPITALS
Ref By:	APOLLO SPECTRA	Date:-	09. P. Scialists in Surgery

## **ULTRASOUND WHOLE ABDOMEN**

**Liver:** Appears normal in size and shows increased parenchymal echogenicity which is most likely due to fatty changes. Intrahepatic biliary radicles are not dilated. CBD and portal vein are normal in calibre.

Gall Bladder: is not seen – Post operative status.

Pancreas and Spleen: Appears normal in size and echotexture.

**Both Kidneys**: are normal in size, shape, and echopattern. The parenchymal thickness is normal and cortico-medullary differentiation is well maintained. Pelvicalyceal systems are not dilated. No calculus or mass lesion is seen. Ureter is not dilated.

**Urinary Bladder:** is minimally distended and shows no obvious calculus or sediments. Bladder wall thickness is normal.

**Uterus** is antiverted and normal in size. It measures 7 x 3.8 cm. Outline is smooth. Myometrium is normal. Endometrial echoes are normal and measures 7 mm

Both ovaries are normal in size.

No obvious adnexal mass is seen. No free fluid seen.

IMPRESSION: FATTY CHANGES IN LIVER GRADE 1

Please correlate clinically and with lab. Investigations.

DR. DEEPIKA AGARWAL CONSULTANT RADIOLOGIST

Dr. DEEP!KA AGARWAL
Consultant Radiologist
DMC No. 56777
Apollo Speciality Hospitals (P) Ltd.
A-2, Chirag Enclave, Greater Kailash-1
New Delhi-110048

**Apollo Spectra Hospitals:** Plot No. A-2, Chirag Enclave, Greater Kailash - 1, New Delhi - 110048 Ph.: 011-40465555, 9910995018 | www.apollospectra.com

Mrs. Santa 9/11/24 36/F



Specialists in Surgery

Lige checked

Go Dov

No Ho many plans

Ho Thyrold We amolication

Localists in Surgery

A 666

No CT 22 July colour Variation of 26

Box ( No Acceptance 6/6 Blf -No Slittamp examinated Shares and Blader on wormand Blader pupil reacts on wormand Blader Fundus (wall Mf

eld Refresh TearTISS BLEXI wonth

Danachyn 9/11/24

**Apollo Spectra Hospitals:** Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

## **Apollo Specialty Hospital Pvt. Ltd.**

DR. (Pof.) Ameet Kishore

SENIOR CONSULTANT SURGEON

MBBS,(AFMC), FRCS(Glass), FRCS(Edin), FRCS-ORL(UK) Ear, Nose, Throat & Neuro-Octology

For Appointment: +91 1140465555

M: +91 9910995018

ollo Spe Specialists in Surgery

**DR. Sharad Nair** 

MBBS,MS,(ENT),FHNORS CONSULTANT SURGEON

Ear, Nose, & Throat Head, Neck & Cancer Surgery

For Appointment: +91 1140465555 M: +91 9910995018

DR. Ashwani Kumar

MBBS, DNB, MNAMS **CONSULTANT SURGEON** 

Ear, Nose, & Throat Surgery Allergy Specialist

For Appointment: +91 1140465555 M: +91 9910995018

No medie

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com



# **DIGITAL X-RAY REPORT**

NAME: SAVITA	DATE: 09.11.2024
UHID NO: 25214	AGE: 36YRS/ SEX: F

## X-RAY CHEST PA VIEW

Both the lung fields show no active parenchymal pathology.

Both the costophrenic angles are clear.

Heart size is normal.

Both the domes of diaphragm are normal.

Bony thorax appears normal.

IMPRESSION: NO SIGNIFICANT ABNORMALITY

Please correlate clinically and with lab investigations

DR. DEEPIKA AGARWAL Consultant Radiologist

Dr. DEEPIKA AGARWAL

Consultant Radiologist

Consultant Radiologist

DMC No. 56777

DMC No. 56777

Apollo Speciality Hospitals (P) Ltd.

Apollo Speciality Hospitals (Page 1888)

A-2, Chirag Enclave, Greater Kailash-1

New Delhi-110048

**Apollo Spectra Hospitals:** Plot No. A-2, Chirag Enclave, Greater Kailash - 1, New Delhi - 110048 Ph.: 011-40465555, 9910995018 | www.apollospectra.com

II III	III haywardhaan hawannanda haywannaha haywannanda aVF		I James Jame	Req. No. :	ID: 25214 SAVITA Female 36Years
Manage of the second of the se	May make a VF	menter france and the second france f	I I what have I have made I have made I have been the second for a former of programmed from the control for t	QRS : 89 ms QT/QTcBz : 314/422 ms P/QRS/T : 53/56/8 ° RV5/SV1 : 1.421/1.016 mV	1-2024 14:03:0 : 108 : 95
			James of the second because of the second because of the second of the s	Report Confirmed by:	Diagnosis Information: Sinus Tachycardia
Marchand Janes Jan					CARDIART



Conducted By:

Referred By

: Mrs. SAVITA

UHID

: SCHI.0000025214

: Dr. MUKESH K GUPTA

: SELF

Age

OP Visit No Conducted Date : 36 Y/F

: SCHIOPV38929 : 09-11-2024 17:00

MITRAL VALVE

AML-Normal/Thickening/Calcification/Flutter/Vegetation/Prolapse/SAM/Doming Morphology

PML-Normal/Thickening/Calcification/Prolapse/Paradoxical motion/Fixed.

Subvalvular deformity Present/Absent.

Score

Normal/Abnormal Doppler Mitral Stenosis

E>A

A>E

Present/Absent MDG mmHg RR Interval msec MVA. \_cm<sup>2</sup>

EDG. \_mmHg Mitral Regurgitation

Absent/Trivial/Mild/Moderate/Severe.

TRICUSPID VALVE

Morphology

Normal/Atresia/Thickening/Calcification/Prolapse/Vegetation/Doming

Doppler

Normal/Abnormal

Present/Absent

RR interval

Tricuspid stenosis EDG mmHg

MDG\_

\_\_\_mmHg Absent/Trivial/Mild/Moderate/Severe Fragmented signals

Tricuspid regurgitation: Velocity msec.

Pred. RVSP=RAP+ mmHg

PULMONARY VALVE

Morphology

Normal/Atresia/Thickening/Doming/Vegetation.

Doppler

Normal/Abnormal. Pulmonary stenosis

Level

Present/Absent mmHg PSG

Pulmonary annulus\_\_\_mm

Pulmonary regurgitation

mmHg. Early diastolic gradient

Absent/Trivial/Mild/Moderate/Severe End diastolic gradient\_mmHg

AORTIC VALVE

Morphology

Normal/Thickening/Calcification/Restricted opening/Flutter/Vegetation

No. of cusps 1/2/3/4

Doppler

Normal/Abnormal

Aortic stenosis

Level Present/Absent \_mmHg

Aortic annulus\_

Aortic regurgitation

Absent/Trivial/Mild/Moderate/Severe

Measureme	nts	Normal Values	Measurements		Normal values
Aorta	2.5	(2.0 - 3.7cm)	LA es	2.7	(1.9 - 4.0 cm)
LV es	2.9	(2.2 - 4.0 cm)	LV ed	4.2	(3.7 - 5.6cm)
IVS ed	0.7	(0.6 - 1.1 cm)	PW (LV)	0.7	(0.6 - 1.1 cm)
RV ed		(0.7 - 2.6cm)	RV Anterior wall		(upto 5 mm)
LVVd (ml)			LVVs (ml)		
EF	60%	(54%-76%)	IVS motion	Nor	mal/Flat/Paradoxical

CHAMBERS:

Normal/Enlarged/Clear/Thrombus/Hypertrophy

Contraction

Normal/Reduced

Regional wall motion abnormality

Absent

LA

Normal/Enlarged/Clear/Thrombus

RA

Normal/Enlarged/Clear/Thrombus

RV

Normal/Enlarged/Clear/Thrombus

Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash - 1, New Delhi - 110048 Ph.: 011-40465555, 9910995018 | www.apollospectra.com

#### Apollo Specialty Hospitals Pvt. Ltd.

CIN - U85100TG2009PTC099414



## **PERICARDIUM**

#### COMMENTS & SUMMARY

- Normal LV systolic function No RWMA, LVEF=60%
- No AR, PR, MR & TR
- No I/C clot or mass
- v Good RV function
- Normal pericardium
- v No pericardial effusion

Dr. M K Gupta M.B.B.S, MD, FIACM Senior Consultant Cardiologist



Apollo Spectra Hospitals: Plot No. A-2, Chirag Enclave, Greater Kailash - 1, New Delhi - 110048 Ph.: 011-40465555, 9910995018 | www.apollospectra.com

## Apollo Specialty Hospitals Pvt. Ltd.

CIN - U85100TG2009PTC099414



09.11.2024.

Mrs. Savita 36 yrs / Female

C/c - Regular Check-Up

DIH- NRH

MH-Pt. is on medication for Thyroid.

Off - Stainst, Calculust

Advised. Qual Prophylamis Full Mouth in. Maxillary & Mandibular teath.

Jr. Alamita

Mis Savila /2648.



ginlac-Vucgint Lablet- at bidhme x7 days. Go with regard

**Apollo Spectra Hospitals:** Plot No. A-2, Chirag Enclave, Greater Kailash -1, New Delhi -110048 Ph: 011-40465555, 9910995018 | www.apollospectra.com

## **Apollo Specialty Hospital Pvt. Ltd.**





Patient Name : Mrs

: Mrs.SAVITA .

Age/Gender UHID/MR No : 36 Y 7 M 25 D/F : SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:31AM

Received

: 09/Nov/2024 10:05AM : 09/Nov/2024 01:45PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF HAEMATOLOGY**

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

----

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology

SIN No:BED240245657



Page 1 of 14





: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:31AM

Received

: 09/Nov/2024 10:05AM : 09/Nov/2024 01:45PM

Reported Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF HAEMATOLOGY**

## ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	10.3	g/dL	12-15	CYANIDE FREE COLOUROMETER
PCV	33.60	%	40-50	PULSE HEIGHT AVERAGE
RBC COUNT	4.29	Million/cu.mm	3.8-4.8	Electrical Impedence
MCV	78.4	fL	83-101	Calculated
MCH	24	pg	27-32	Calculated
MCHC	30.6	g/dL	31.5-34.5	Calculated
R.D.W	18.2	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	9,550	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT	Γ (DLC)			
NEUTROPHILS	63.1	%	40-80	Electrical Impedance
LYMPHOCYTES	25.9	%	20-40	Electrical Impedance
EOSINOPHILS	3.5	%	1-6	Electrical Impedance
MONOCYTES	6.9	%	2-10	Electrical Impedance
BASOPHILS	0.6	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	6026.05	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2473.45	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	334.25	Cells/cu.mm	20-500	Calculated
MONOCYTES	658.95	Cells/cu.mm	200-1000	Calculated
BASOPHILS	57.3	Cells/cu.mm	0-100	Calculated
Neutrophil lymphocyte ratio (NLR)	2.44		0.78- 3.53	Calculated
PLATELET COUNT	334000	cells/cu.mm	150000-410000	IMPEDENCE/MICROSCOPY
ERYTHROCYTE SEDIMENTATION RATE (ESR)	25	mm at the end of 1 hour	0-20	Modified Westergren
PERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC WITH FEW MICROCYTIC HYPOCHROMIC CELLS.

TLC , DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN. PLATELETS ARE ADEQUATE.

Page 2 of 14



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:BED240245657





: Mrs.SAVITA .

Age/Gender UHID/MR No

: 36 Y 7 M 25 D/F : SCHI.0000025214

Visit ID

: SCHIOPV38929

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:31AM

Received

: 09/Nov/2024 10:05AM

Reported

Status

: 09/Nov/2024 01:45PM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF HAEMATOLOGY**

ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:BED240245657

Page 3 of 14





 Patient Name
 : Mrs.SAVITA .

 Age/Gender
 : 36 Y 7 M 25 D/F

 UHID/MR No
 : SCHI.0000025214

Visit ID : SCHIOPV38929

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SFSDFGS Collected : 09/Nov/2024 09:31AM
Received : 09/Nov/2024 10:05AM
Reported : 09/Nov/2024 01:51PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF HAEMATOLOGY**

## ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
BLOOD GROUP ABO AND RH FACTOR	R, WHOLE BLOOD EDTA		<u>'</u>	<u>'</u>
BLOOD GROUP TYPE	В			Forward & Reverse Grouping with Slide/Tube Aggluti
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination

Page 4 of 14



Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:BED240245657





: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No Visit ID : SCHI.0000025214

Ref Doctor

: SCHIOPV38929 : Dr.SELF

Emp/Auth/TPA ID : SFSDFGS

Collected

: 09/Nov/2024 01:51PM

Received

: 09/Nov/2024 02:55PM

Reported Status : 09/Nov/2024 04:41PM

Sponsor Name

: Final Report

•

: ARCOFEMI HEALTHCARE LIMITED

#### DEPARTMENT OF BIOCHEMISTRY

#### ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GLUCOSE, FASTING, NAF PLASMA	106	mg/dL	70-100	GOD - POD

#### **Comment:**

## As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

#### Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Test Name	Result	Unit	Bio. Ref. Interval	Method
GLUCOSE, POST PRANDIAL (PP), 2 HOURS, SODIUM FLUORIDE PLASMA (2 HR)	133	mg/dL	70-140	GOD - POD

#### **Comment:**

It is recommended that FBS and PPBS should be interpreted with respect to their Biological reference ranges and not with each other.

Conditions which may lead to lower postprandial glucose levels as compared to fasting glucose levels may be due to reactive hypoglycemia, dietary meal content, duration or timing of sampling after food digestion and absorption, medications such as insulin preparations, sulfonylureas, amylin analogues, or conditions such as overproduction of insulin.

Page 5 of 14



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:PLP1488010







: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:32AM

Received

: 09/Nov/2024 12:57PM

Reported

Status

: 09/Nov/2024 03:22PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF BIOCHEMISTRY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
HBA1C (GLYCATED HEMOGLOBIN),	WHOLE BLOOD EDTA			
HBA1C, GLYCATED HEMOGLOBIN	5.6	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	114	mg/dL		Calculated

#### **Comment:**

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 - 6.4
DIABETES	≥ 6.5
DIABETICS	
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 - 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic

Control by American Diabetes Association guidelines 2023.

- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control A: HbF >25%
  - B: Homozygous Hemoglobinopathy.

(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Page 6 of 14



Dr Nidhi Sachdev M.B.B.S, MD(Pathology) Consultant Pathologist

SIN No:EDT240094067





: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:32AM

Received

: 09/Nov/2024 10:02AM

Reported Status

: 09/Nov/2024 01:23PM

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF BIOCHEMISTRY**

## ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
LIPID PROFILE , SERUM		'	1	
TOTAL CHOLESTEROL	184	mg/dL	<200	CHE/CHO/POD
TRIGLYCERIDES	140	mg/dL	<150	Enzymatic
HDL CHOLESTEROL	41	mg/dL	>40	CHE/CHO/POD
NON-HDL CHOLESTEROL	143	mg/dL	<130	Calculated
LDL CHOLESTEROL	115	mg/dL	<100	Calculated
VLDL CHOLESTEROL	28	mg/dL	<30	Calculated
CHOL / HDL RATIO	4.49		0-4.97	Calculated
ATHEROGENIC INDEX (AIP)	0.17		<0.11	Calculated

#### **Comment:**

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

Page 7 of 14









: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:32AM

Received Reported : 09/Nov/2024 10:02AM : 09/Nov/2024 01:23PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF BIOCHEMISTRY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
LIVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.70	mg/dL	0.20-1.30	DIAZO METHOD
BILIRUBIN CONJUGATED (DIRECT)	0.30	mg/dL	0.0-0.3	Calculated
BILIRUBIN (INDIRECT)	0.40	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	24	U/L	<35	Visible with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	32.0	U/L	14-36	UV with P-5-P
AST (SGOT) / ALT (SGPT) RATIO (DE RITIS)	1.3		<1.15	Calculated
ALKALINE PHOSPHATASE	78.00	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	8.30	g/dL	6.3-8.2	Biuret
ALBUMIN	4.70	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	3.60	g/dL	2.0-3.5	Calculated
A/G RATIO	1.31		0.9-2.0	Calculated

## **Comment:**

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin) Common patterns seen:

- 1. Hepatocellular Injury:
- \*AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.\*ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with ALP. AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.
- 2. Cholestatic Pattern:\*ALP Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in pregnancy, impacted by age and sex.\*Bilirubin elevated- predominantly direct , To establish the hepatic origin correlation with elevated GGT helps.
- 3. Synthetic function impairment:\*Albumin-Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
- 4. Associated tests for assessment of liver fibrosis Fibrosis-4 and APRI Index.

Page 8 of 14



Dr. SHWETA GUPTA
MBBS,MD (Pathology)
Consultant Pathology
SIN No:SE04843250





: Mrs.SAVITA .

Age/Gender UHID/MR No : 36 Y 7 M 25 D/F : SCHI.0000025214

Visit ID

: SCHIOPV38929

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : SFSDFGS Collected

: 09/Nov/2024 09:32AM

Received Reported : 09/Nov/2024 10:02AM : 09/Nov/2024 01:23PM

Status Sponsor Name : Final Report

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF BIOCHEMISTRY**

## ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method			
RENAL PROFILE/KIDNEY FUNCTION TEST (RFT/KFT), SERUM							
CREATININE	0.60	mg/dL	0.5-1.04	Creatinine amidohydrolase			
UREA	19.60	mg/dL	15-36	Urease			
BLOOD UREA NITROGEN	9.2	mg/dL	8.0 - 23.0	Calculated			
URIC ACID	5.30	mg/dL	2.5-6.2	Uricase			
CALCIUM	10.90	mg/dL	8.4 - 10.2	Arsenazo-III			
PHOSPHORUS, INORGANIC	3.20	mg/dL	2.5-4.5	PMA Phenol			
SODIUM	143	mmol/L	135-145	Direct ISE			
POTASSIUM	5.2	mmol/L	3.5-5.1	Direct ISE			
CHLORIDE	112	mmol/L	98 - 107	Direct ISE			
PROTEIN, TOTAL	8.30	g/dL	6.3-8.2	Biuret			
ALBUMIN	4.70	g/dL	3.5 - 5	Bromocresol Green			
GLOBULIN	3.60	g/dL	2.0-3.5	Calculated			
A/G RATIO	1.31		0.9-2.0	Calculated			

Page 9 of 14







: Mrs.SAVITA .

Age/Gender : 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF

: SFSDFGS

Collected

: 09/Nov/2024 09:32AM

Received

: 09/Nov/2024 10:02AM

Reported Status : 09/Nov/2024 10:51AM : Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF BIOCHEMISTRY**

## ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	32.00	U/L	12-43	Glyclyclycine Nitoranalide

Page 10 of 14









: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No Visit ID : SCHI.0000025214 : SCHIOPV38929

Ref Doctor

: Dr.SELF

Emp/Auth/TPA ID : SFSDFGS

Collected

: 09/Nov/2024 09:32AM

Received Reported : 09/Nov/2024 12:58PM : 09/Nov/2024 02:40PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

#### **DEPARTMENT OF IMMUNOLOGY**

## ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method		
THYROID PROFILE TOTAL (T3, T4, TSH), SERUM						
TRI-IODOTHYRONINE (T3, TOTAL)	1.1	ng/mL	0.87-1.78	CLIA		
THYROXINE (T4, TOTAL)	10.49	μg/dL	5.48-14.28	CLIA		
THYROID STIMULATING HORMONE (TSH)	5.512	μIU/mL	0.38-5.33	CLIA		

#### **Comment:**

For pregnant females	Bio Ref Range for TSH in uIU/ml (As per American Thyroid Association)			
First trimester	0.1 - 2.5			
Second trimester	0.2 - 3.0			
Third trimester	0.3 - 3.0			

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- **4.** Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	<b>T3</b>	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Treatment.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes

Page 11 of 14



Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

SIN No:SPL24146223







: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID

: SCHIOPV38929

Ref Doctor Emp/Auth/TPA ID : Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:32AM

Received

: 09/Nov/2024 12:58PM

Reported

: 09/Nov/2024 02:40PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF IMMUNOLOGY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma
------	------	------	------	--

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

SIN No:SPL24146223



Page 12 of 14





: Mrs.SAVITA .

Age/Gender

: 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID Ref Doctor : SCHIOPV38929

Emp/Auth/TPA ID

: Dr.SELF : SFSDFGS Collected

: 09/Nov/2024 09:32AM

Received

: 09/Nov/2024 01:44PM

Reported

: 09/Nov/2024 01:53PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF CLINICAL PATHOLOGY**

## ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
COMPLETE URINE EXAMINATION (	CUE) , URINE			<u>'</u>
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Physical Measurement
pH	6.0		5-7.5	Double Indicator
SP. GRAVITY	1.030		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	Protein Error Of Indicator
GLUCOSE	NEGATIVE		NEGATIVE	Glucose Oxidase
URINE BILIRUBIN	NEGATIVE		NEGATIVE	Azo Coupling Reaction
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	Sodium Nitro Prusside
UROBILINOGEN	NORMAL		NORMAL	Modifed Ehrlich Reaction
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	Leucocyte Esterase
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOP	1		
PUS CELLS	2-4	/hpf	0-5	Microscopy
EPITHELIAL CELLS	1-2	/hpf	<10	Microscopy
RBC	ABSENT	/hpf	0-2	Microscopy
CASTS	ABSENT		0-2 Hyaline Cast	Microscopy
CRYSTALS	ABSENT		ABSENT	Microscopy

#### **Comment:**

All urine samples are checked for adequacy and suitability before examination. All abnormal chemical examination are rechecked and verified by manual methods. Microscopy findings are reported as an average of 10 high power fields.

Page 13 of 14



Dr. SHWETA GUPTA MBBS,MD (Pathology) Consultant Pathology SIN No:UR2419305





Patient Name : Mrs.SAVITA . Age/Gender : 36 Y 7 M 25 D/F

UHID/MR No

: SCHI.0000025214

Visit ID

: SCHIOPV38929

Ref Doctor Emp/Auth/TPA ID : SFSDFGS

: Dr.SELF

Collected Received

: 09/Nov/2024 09:32AM

Reported

: 09/Nov/2024 01:44PM : 09/Nov/2024 01:53PM

Status

: Final Report

Sponsor Name

: ARCOFEMI HEALTHCARE LIMITED

## **DEPARTMENT OF CLINICAL PATHOLOGY**

#### ARCOFEMI - MEDIWHEEL - FULL BODY HEALTH ANNUAL PLUS CHECK - FEMALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
URINE GLUCOSE(POST PRANDIAL)	NEGATIVE		NEGATIVE	GOD-POD
Test Name	Result	Unit	Bio. Ref. Interval	Method
URINE GLUCOSE(FASTING)				

\*\*\* End Of Report \*\*\*

Result/s to Follow: LBC PAP SMEAR

Page 14 of 14







Patient Name : Mrs.SAVITA Age/Gender : 36 Y 7 M 25 D/F

UHID/MR No : SCHI.0000025214 Visit ID : SCHIOPV38929

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : SFSDFGS Collected : 09/Nov/2024 09:32AM Received : 09/Nov/2024 01:44PM

Reported : 09/Nov/2024 01:53PM

: Final Report : ARCOFEMI HEALTHCARE LIMITED Sponsor Name

#### TERMS AND CONDITIONS GOVERNING THIS REPORT

- 1. Reported results are for information and interpretation of the referring doctor or such other medical professionals, who understandreporting units, reference ranges and limitation of technologies. Laboratories not be responsible for any interpretation whatsoever.
- 2. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the verifications of parrticulars have been confirmed by the patient or his / her representative at the point of generation of said specimen.

Status

- 3. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same parameter for the same patient (within subject biological variation).
- 4. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be communicated to the assigned regulatory bodies.
- 5. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of the laboratory.
- 6. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only.

hweta Dr. SHWETA GUPTA MBBS, MD (Pathology) Consultant Pathology SIN No:UF012152



UHID : SCHI.0000025214 OP Visit No : SCHIOPV38929 Conducted By: : Dr. MUKESH K GUPTA Conducted Date : 09-11-2024 17:00

Referred By : SELF

<b>MITRAL</b>	VALVE
111111111111	7 / 1 1 7 1 2

Morphology AML-Normal/Thickening/Calcification/Flutter/Vegetation/Prolapse/SAM/Doming.

PML-Normal/Thickening/Calcification/Prolapse/Paradoxical motion/Fixed.

Subvalvular deformity Present/Absent. Score :

Doppler Normal/Abnormal E>A A>E

Mitral Stenosis Present/Absent RR Interval msec

EDG\_\_\_mmHg MDG\_\_\_mmHg MVA\_\_\_cm<sup>2</sup>

Mitral Regurgitation **Absent**/Trivial/Mild/Moderate/Severe.

#### TRICUSPID VALVE

Morphology Normal/Atresia/Thickening/Calcification/Prolapse/Vegetation/Doming.

Doppler Normal/Abnormal

Tricuspid stenosis Present/Absent RR interval msec.

EDG mmHg MDG mmHg

Tricuspid regurgitation : <u>Absent</u>/Trivial/Mild/Moderate/Severe Fragmented signals

Velocity msec. Pred. RVSP=RAP+ mmHg

PULMONARY VALVE

Morphology Normal/Atresia/Thickening/Doming/Vegetation.

Doppler Normal/Abnormal.

Pulmonary stenosis Present/**Absent** Level

PSG mmHg Pulmonary annulus mm

Pulmonary regurgitation Absent/Trivial/Mild/Moderate/Severe

Early diastolic gradient mmHg. End diastolic gradient mmHg

### **AORTIC VALVE**

Morphology Normal/Thickening/Calcification/Restricted opening/Flutter/Vegetation

No. of cusps 1/2/3/4

Doppler Normal/Abnormal

Aortic stenosis Present/Absent Level

PSG mmHg Aortic annulus mm

Aortic regurgitation Absent/Trivial/Mild/Moderate/Severe.

MeasurementsNormal ValuesMeasurementsNormal valuesAorta2.5(2.0 – 3.7cm)LA es2.7(1.9 – 4.0cm)

UHID : SCHI.0000025214 OP Visit No : SCHIOPV38929 Conducted By: : Dr. MUKESH K GUPTA Conducted Date : 09-11-2024 17:00

Referred By : SELF

2.9 LV ed 4.2 (3.7 - 5.6cm)LV es (2.2 - 4.0 cm)IVS ed 0.7 (0.6 - 1.1 cm)PW (LV) 0.7 (0.6 - 1.1 cm)RV ed (0.7 - 2.6cm)RV Anterior wall (upto 5 mm)

LVVd (ml) LVVs (ml)

EF 60% (54%-76%) IVS motion Normal/Flat/Paradoxical

## **CHAMBERS:**

LV <u>Normal/Enlarged/Clear/Thrombus/Hypertrophy</u>

Contraction Normal/Reduced

Regional wall motion abnormality Absent

LA <u>Normal/Enlarged/Clear/Thrombus</u>

RA <u>Normal/Enlarged/Clear/Thrombus</u>

RV <u>Normal/Enlarged/Clear/Thrombus</u>

# **PERICARDIUM**

## **COMMENTS & SUMMARY**

- v Normal LV systolic function
- v No RWMA, LVEF=60%
- v No AR,PR,MR & TR
- v No I/C clot or mass
- v Good RV function
- v Normal pericardium
- v No pericardial effusion

UHID : SCHI.0000025214 OP Visit No : SCHIOPV38929 Conducted By: : Dr. MUKESH K GUPTA Conducted Date : 09-11-2024 17:00

Referred By : SELF

Dr. M K Gupta M.B.B.S, MD,FIACM Senior Consultant Cardiologist

UHID : SCHI.0000025214 OP Visit No : SCHIOPV38929

Conducted By: : Conducted Date :

Referred By : SELF

Patient Name : Mrs. SAVITA . Age : 36 Y/F

UHID : SCHI.0000025214 OP Visit No : SCHIOPV38929

Conducted By : Conducted Date :

Referred By : SELF